353278-57-6 Usage
Uses
Used in Pharmaceutical Industry:
2-Bromo-4-methoxybenzamide is used as a key intermediate in the synthesis of various drugs for its versatile chemical properties. It plays a significant role in the development of anti-inflammatory and anti-cancer medications, contributing to the treatment and management of these conditions.
Used in Agrochemical Industry:
2-broMo-4-MethoxybenzaMide is also used as a potential herbicide, indicating its application in controlling, preventing, or killing unwanted plants in agricultural settings. Its study for this purpose highlights its potential to be integrated into products that enhance crop yield and quality by managing weed growth.
Used in Chemical Research:
2-Bromo-4-methoxybenzamide serves as a subject of study in chemical research, where its properties and reactions are explored to understand its behavior and potential applications in various chemical processes and compound development.
Check Digit Verification of cas no
The CAS Registry Mumber 353278-57-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,5,3,2,7 and 8 respectively; the second part has 2 digits, 5 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 353278-57:
(8*3)+(7*5)+(6*3)+(5*2)+(4*7)+(3*8)+(2*5)+(1*7)=156
156 % 10 = 6
So 353278-57-6 is a valid CAS Registry Number.
353278-57-6Relevant articles and documents
Discovery of highly potent SARS-CoV-2 Mpro inhibitors based on benzoisothiazolone scaffold
Chen, Weixiong,Feng, Bo,Han, Sheng,Wang, Peipei,Chen, Wuhong,Zang, Yi,Li, Jia,Hu, Youhong
supporting information, (2022/01/14)
The COVID-19 pandemic has drastically impacted global economies and public health. Although vaccine development has been successful, it was not sufficient against more infectious mutant strains including the Delta variant indicating a need for alternative treatment strategies such as small molecular compound development. In this work, a series of SARS-CoV-2 main protease (Mpro) inhibitors were designed and tested based on the active compound from high-throughput diverse compound library screens. The most efficacious compound (16b-3) displayed potent SARS-CoV-2 Mpro inhibition with an IC50 value of 116 nM and selectivity against SARS-CoV-2 Mpro when compared to PLpro and RdRp. This new class of compounds could be used as potential leads for further optimization in anti COVID-19 drug discovery.